{
    "symbol": "AIH",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-29 12:00:25",
    "content": " Thank you, everyone, for joining the call today. In the third quarter of 2022, total revenue decreased 0.3% year-on-year to RMB 167 million, primarily attributable to the divestment of underperforming assets in the 2021 and the first 3 quarters of 2022 and the temporary closure of several treatment centers due to the pandemic preventative requirements in the third quarter of 2022. Selling expenses was RMB 61.5 million, representing 36.8% of the company's total revenue in the third quarter of 2022. General and admin expenses were RMB 45.5 million, representing a decrease of 12.6%, primarily due to the divestment of underperforming assets in the 2021 and the first three quarters of 2022. As a result of the foregoing, the company recorded a loss of RMB 52.4 million for the third quarter of 2022 compared with a loss of RMB 30.3 million in the third quarter of 2021. Adjusted EBITDA for the third quarter of 2022 was RMB 10.6 million, rebounded from a loss of RMB 30 million in the third quarter of 2021. Adjusted loss after tax for the third quarter of 2022 narrowed to RMB 3.7 million, compared with a loss of RMB 17.2 million in the third quarter of 2021. In terms of our operating performance, as a result of a temporary business and suspension of several treatment centers in the third quarter of 2022, the company recorded a decrease of 13.5% year-on-year in the total active customers. Average spending per customer increased by 15.2% from RMB 2,529 in third quarter of 2021 to RMB 2,915 in the third quarter of 2022, primarily driven by the sales of high-end bio-stimulating fillers. Thank you, everyone, for joining the call today. Thank you, everyone, for attending Aesthetic Medical International's third quarter of 2022 earnings conference call."
}